Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss linked to higher heart disease risk in both men and women.

This meta-analysis found that lower serum SHBG levels are associated with an increased risk of PCOS, and improving SHBG levels through treatment may reduce PCOS complications.

This review discusses the link between insulin resistance and skin conditions such as acanthosis nigricans and psoriasis, but provides no new clinical results.

This review discusses the multifactorial origins and pathophysiology of PCOS and highlights the effectiveness of lifestyle modifications as a first-line intervention, reporting no new research results.

In this study, short-term liraglutide treatment led to significant weight loss in obese women with newly diagnosed PCOS and a higher metabolic risk profile compared to metformin.

This study suggests that adding metformin to diet and exercise improves insulin resistance and hyperandrogenism in women with PCOS, though lifestyle changes alone may enhance menstrual cycles.

This study found that ZDHHC13 deficiency in mice is associated with abnormal liver function, lipid metabolism issues, and impaired mitochondrial function, highlighting ZDHHC13's regulatory role in liver metabolism.

This review discusses the relationship between SHBG, NAFLD, and PCOS and reports no new clinical results; the authors highlight low hepatic SHBG production as potentially significant in PCOS pathogenesis.

This study discusses the use of oral contraceptives as a treatment for hyperandrogenism, showing improvement in hirsutism and acne for many women and possibly providing metabolic benefits with certain formulations.

This study observed that among women with polycystic ovary syndrome, those with the most severe phenotype showed the highest levels of metabolic disturbances, indicating the need for metabolic screening in these cases.

This article reviews dietary recommendations for managing polycystic ovary syndrome and provides evidence that diet changes can improve the androgen profile in affected women, but it reports no new clinical results.

This review compiles current information about Eclipta prostrata, traditional uses, and its promising pharmacological properties, like hepatoprotective and anti-inflammatory effects, but emphasizes that more research is needed to fully understand its mechanisms and ensure safety for clinical application.

This review summarizes the ethno-medicinal uses, phytochemical constituents, and biological activities of Acorus calamus, highlighting its potential therapeutic benefits and the importance of further scientific work on this plant.

To diagnose Polycystic Ovarian Syndrome, two out of three signs—irregular periods, high male hormone levels, or cysts on the ovaries—are needed.

This review suggests that quercetin supplementation may benefit ovarian functions and hormonal levels in polycystic ovary syndrome, though further high-quality trials are needed for confirmation.

This study found that melatonin significantly improved metabolic and reproductive parameters in PCOS-induced rats, with effects similar to metformin.

This article discusses the complexities of androgen and antiandrogen therapies in women, detailing diagnostic measures, the effects on libido, and the potential benefits of new progestins with antiandrogenic properties, but presents no new empirical findings.

In this study on rats, rutin showed dose-dependent improvements in hormonal, antioxidant, and lipid profiles related to polycystic ovary syndrome, with effects comparable to metformin.

This study found that patients with severe vertex pattern androgenetic alopecia had significantly higher carotid intima-media thickness, suggesting an increased risk of subclinical atherosclerosis compared to other alopecia patterns and healthy controls.

This study found that among middle-aged Korean women, those with metabolic syndrome had a higher risk of androgenetic alopecia, while no significant association was observed in men.

This study reported that almost 25% of women with PCOS were diagnosed with NAFLD, and 32.7% to 44.6% had metabolic syndrome, with higher prevalence in those with both conditions.

This study supports evaluating metabolic syndrome and insulin resistance in young males with advanced androgenic alopecia to potentially reduce future cardiovascular and type 2 diabetes risks.

Metformin improves menstrual cycles and hormone levels in women with PCOS, mostly within the first 6 months.

This study found that women with polycystic ovary syndrome phenotypes A and B had the highest prevalence of metabolic syndrome, and that the visceral adiposity index may help predict metabolic risk.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This article reviews androgen excess and cardiometabolic risks in women, highlighting increased cardiovascular disease risk in those with polycystic ovary syndrome, but reports no new clinical results.

This study found no significant differences in metabolic characteristics between different phenotypes of PCOS or between women with PCOS and healthy controls among reproductive-aged Iranian women.

This study found that young women with polycystic ovary syndrome had a higher risk of developing hypertension and metabolic syndrome compared to healthy controls, although these risks decreased after age 40.

This review explores the relationship between androgenetic alopecia and metabolic syndrome, suggesting an association that supports considering cardiovascular risk assessments in patients with this type of hair loss.

This study found that enzyme replacement therapy in mice with a severe form of classical homocystinuria improved metabolic patterns and alleviated many clinical symptoms.